Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma

Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma

Abstract Background Adrenocortical carcinoma (ACC) is a rare malignancy without good treatment options. There are limited data about the use of immunotherapy in ACC. We investigated the efficacy and safety of pembrolizumab in patients with metastatic ACC. Methods This is a pre-specified cohort of a...

Full description

Bibliographic Details
Main Authors: Mouhammed Amir Habra, Bettzy Stephen, Matthew Campbell, Kenneth Hess, Coya Tapia, Mingxuan Xu, Jordi Rodon Ahnert, Camilo Jimenez, Jeffrey E. Lee, Nancy D. Perrier, Russell R. Boraddus, Shubham Pant, Vivek Subbiah, David S. Hong, Abdulrazzak Zarifa, Siqing Fu, Daniel D. Karp, Funda Meric-Bernstam, Aung Naing
Format: Article
Language:English
Published: BMJ Publishing Group 2019-09-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Adrenocortical carcinoma
Immunotherapy
Tumor-infiltrating lymphocytes
Microsatellite instability
Programmed cell death ligand
Adverse events
Online Access:http://link.springer.com/article/10.1186/s40425-019-0722-x

Internet

http://link.springer.com/article/10.1186/s40425-019-0722-x

Similar Items